BioSpace

Neurocrine defends Prader-Willi drug after another patient death

Neurocrine Biosciences will conduct a new study for the rare disease drug Vykat to explore dosing and safety in patients with Prader-Willi syndrome who have complex health issues.

By BioSpace

1 min read
Neurocrine defends Prader-Willi drug after another patient death
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights